(19)
(11) EP 2 289 512 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.08.2017 Bulletin 2017/31

(45) Mention of the grant of the patent:
07.06.2017 Bulletin 2017/23

(21) Application number: 10158720.2

(22) Date of filing: 23.01.2004
(51) International Patent Classification (IPC): 
A61K 31/4025(2006.01)
A61P 17/10(2006.01)
 A61K 9/12(2006.01)

(54)

Pharmaceutical foam

Pharmazeutischer Schaum

Mousse pharmaceutique

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 24.01.2003 US 442280 P
13.03.2003 US 454832 P

(43) Date of publication of application:
02.03.2011 Bulletin 2011/09

(62) Application number of the earlier application in accordance with Art. 76 EPC:
04704507.5 / 1592420

(73) Proprietor: Stiefel Research Australia Pty Ltd
Boronia 3155 (AU)

(72) Inventors:
  • Abram, Albert Zorko
    Wantirna, Victoria 3152 (AU)
  • Fuchshuber, Lilian
    Narre Warren, Victoria 3805 (AU)

(74) Representative: Reeves, Julie Frances 
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-96/27376
US-A- 5 466 446
US-A- 5 783 202
US-B1- 6 428 772
 GB-A- 1 561 423
US-A- 5 679 324
US-A- 6 013 637
   
  • WOODFORD R ET AL: "BIOAVAILABILITY AND ACTIVITY OF TOPICAL CORTICOSTEROIDS FROM A NOVEL DRUG DELIVERY SYSTEM, THE AEROSOL QUICK-BREAK FOAM", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US LNKD- DOI:10.1002/JPS.2600660125, vol. 66, no. 1, 1 January 1977 (1977-01-01), pages 99-103, XP000996069, ISSN: 0022-3549
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).